Evaluation of the levels of inflammatory proteins, such as Iba1 and GFAP, in brain tissues of patients with Alzheimer’s disease by western blot analysis

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and behavioral changes. The pathological hallmarks of AD include amyloid-beta plaques, tau tangles, and significant neuroinflammation. Inflammation in the brain plays a central role in the development and progression of AD, involving various glial cell types, including microglia and astrocytes. Recent studies have highlighted the potential of inflammatory proteins such as ionized calcium-binding adapter molecule 1 (Iba1) and glial fibrillary acidic protein (GFAP) as key biomarkers for AD. Iba1 is a protein predominantly expressed in microglia, whereas GFAP is a protein specific to astrocytes. This study aims to evaluate the levels of these inflammatory proteins in post-mortem brain tissues from AD patients using Western blot analysis. By quantifying the expression of Iba1 and GFAP, we aim to provide insights into the degree of neuroinflammation in AD and its potential as a diagnostic or prognostic tool. Our findings suggest that increased levels of Iba1 and GFAP are associated with advanced stages of AD, supporting their role as biomarkers for neuroinflammation in Alzheimer’s disease.